Cell-penetrating, guanidinium-rich molecular transporters for overcoming efflux-mediated multidrug resistance

Molecular Pharmaceutics

Volumn 11, Issue 8, 2014, Pages 2553-2565

  Vargas, Jessica R ^a   Stanzl, Erika Geihe ^a   Teng, Nelson N H ^b   Wender, Paul A ^a  

^a STANFORD UNIVERSITY   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

cancer; cell penetrating peptide (CPP); drug delivery; guanidinium rich molecular transporters; molecular transporters; multidrug resistance; octaarginine; P glycoprotein

Indexed keywords

ANTINEOPLASTIC AGENT; CELL PENETRATING PEPTIDE; DEXTRO OCTAARGININE; GUANIDINE DERIVATIVE; MULTIDRUG RESISTANCE PROTEIN; PACLITAXEL; UNCLASSIFIED DRUG; GUANIDINE; OCTAARGININE; OLIGOPEPTIDE; PEPTIDE; WATER;

ANIMAL CELL; ANIMAL EXPERIMENT; CONTROLLED STUDY; DRUG CONJUGATION; DRUG DESIGN; DRUG RELEASE; EX VIVO STUDY; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; OVARIAN CANCER CELL LINE; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; TARGET CELL; ANIMAL; CELL MEMBRANE; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; DRUG RESISTANCE; FEMALE; METABOLISM; OVARIAN NEOPLASMS; PROTEIN TRANSPORT; SOLUBILITY; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ANIMALS; BIOLOGICAL TRANSPORT; CELL LINE, TUMOR; CELL MEMBRANE; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; GUANIDINE; HUMANS; MICE; OLIGOPEPTIDES; OVARIAN NEOPLASMS; P-GLYCOPROTEIN; PACLITAXEL; PEPTIDES; PROTEIN TRANSPORT; RNA INTERFERENCE; SOLUBILITY; WATER;

EID: 84905459949     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp500161z     Document Type: Review

References (108)

1. World Health Organization. Towards Universal Access to Diagnosisand Treatment of Multidrug-Resistant and Extensively Drug-ResistantTuberculosis by 2015. In WHO Progress Report 2011 WHO/HTM/TB/2011.3; World Health Organization: Geneva, Switzerland, 2011.
2. Silva, P. E. A. D.; Palomino, J. C. Molecular Basis and Mechanisms of Drug Resistance in Mycobacterium Tuberculosis: Classical and New Drugs J. Antimicrob. Chemother. 2011, 66, 1417-1430
3. Longley, D. B.; Johnston, P. G. Molecular Mechanisms of Drug Resistance J. Pathol. 2005, 205, 275-292
4. Abouzeed, Y. M.; Baucheron, S.; Cloeckaert, A. ramR Mutations Involved in Efflux-Mediated Multidrug Resistance in Salmonella Enterica Serovar Typhimurium Antimicrob. Agents Chemother. 2008, 52, 2428-2434
5. Szakács, G.; Paterson, J. K.; Ludwig, J. A.; Booth-Genthe, C.; Gottesman, M. M. Targeting Multidrug Resistance in Cancer Nat. Rev. Drug Discovery 2006, 5, 219-234
6. Colabufo, N. A.; Berardi, F.; Cantore, M.; Contino, M.; Inglese, C.; Niso, M.; Perrone, R. Perspectives of P-Glycoprotein Modulating Agents in Oncology and Neurodegenerative Diseases: Pharmaceutical, Biological, and Diagnostic Potentials J. Med. Chem. 2010, 53, 1883-1897
7. Mohandas, N.; Winardi, R.; Knowles, D.; Leung, A.; Parra, M.; George, E.; Conboy, J.; Chasis, J. Molecular Basis for Membrane Rigidity of Hereditary Ovalocytosis. A Novel Mechanism Involving the Cytoplasmic Domain of Band 3 J. Clin. Invest. 1992, 89, 686-692
8. Cowman, A. F.; Karcz, S.; Galatis, D.; Culvenor, J. G. A P-Glycoprotein Homologue of Plasmodium Falciparum Is Localized on the Digestive Vacuole J. Cell Biol. 1991, 113, 1033-1042
9. Rodrigues, L.; Machado, D.; Couto, I.; Amaral, L.; Viveiros, M. Contribution of Efflux Activity to Isoniazid Resistance in the Mycobacterium Tuberculosis Complex Infect. Genet. Evol. 2012, 12, 695-700
10. Kartner, N.; Riordan, J. R.; Ling, V. Cell Surface P-Glycoprotein Associated with Multidrug Resistance in Mammalian Cell Lines Science 1983, 221, 1285-1288
11. Sharom, F. J. ABC Multidrug Transporters: Structure, Function and Role in Chemoresistance Pharmacogenomics 2008, 9, 105-127
12. Lam, F. C.; Liu, R.; Lu, P.; Shapiro, A. B.; Renoir, J.-M.; Sharom, F. J.; Reiner, P. B. B-Amyloid Efflux Mediated by P-Glycoprotein J. Neurochem. 2001, 76, 1121-1128
13. Schuetz, E. G.; Beck, W. T.; Schuetz, J. D. Modulators and Substrates of P-Glycoprotein and Cytochrome P4503A Coordinately up-Regulate These Proteins in Human Colon Carcinoma Cells Mol. Pharmacol. 1996, 49, 311-318
14. Gatlik-Landwojtowicz, E.; Äänismaa, P.; Seelig, A. Quantification and Characterization of P-Glycoprotein-Substrate Interactions Biochemistry 2006, 45, 3020-3032
15. Aller, S. G.; Yu, J.; Ward, A.; Weng, Y.; Chittaboina, S.; Zhuo, R.; Harrell, P. M.; Trinh, Y. T.; Zhang, Q.; Urbatsch, I. L.; Chang, G. Structure of P-Glycoprotein Reveals a Molecular Basis for Poly-Specific Drug Binding Science 2009, 323, 1718-1722
16. Sarkadi, B.; Homolya, L.; Szakács, G.; Váradi, A. Human Multidrug Resistance ABCB and ABCG Transporters: Participation in a Chemoimmunity Defense System Physiol. Rev. 2006, 86, 1179-1236
17. Zajchowski, D. A.; Karlan, B. Y.; Shawver, L. K. Treatment-Related Protein Biomarker Expression Differs between Primary and Recurrent Ovarian Carcinomas Mol. Cancer Ther. 2011, 11, 492-502
18. Murray, S.; Briasoulis, E.; Linardou, H.; Bafaloukos, D.; Papadimitriou, C. Taxane Resistance in Breast Cancer: Mechanisms, Predictive Biomarkers and Circumvention Strategies Cancer Treat. Rev. 2012, 38, 890-903
19. Yeh, J. J.; Hsu, W. H.; Wang, J. J.; Ho, S. T.; Kao, A. Predicting Chemotherapy Response to Paclitaxel-Based Therapy in Advanced Non-Small-Cell Lung Cancer with P-Glycoprotein Expression Respiration 2003, 70, 32-35
20. Chiou, J.-F.; Liang, J.-A.; Hsu, W.-H.; Wang, J.-J.; Ho, S.-T.; Kao, A. Comparing the Relationship of Taxol-Based Chemotherapy Response with P-Glycoprotein and Lung Resistance-Related Protein Expression in Non-Small Cell Lung Cancer Lung 2003, 181, 267-273
21. Dean, M.; Fojo, T.; Bates, S. Tumour Stem Cells and Drug Resistance Nat. Rev. Cancer 2005, 5, 275-284
22. Flesken-Nikitin, A.; Hwang, C.-I.; Cheng, C.-Y.; Michurina, T. V.; Enikolopov, G.; Nikitin, A. Y. Ovarian Surface Epithelium at the Junction Area Contains a Cancer-Prone Stem Cell Niche Nature 2013, 495, 241-245
23. Chen, J.; Li, Y.; Yu, T.-S.; McKay, R. M.; Burns, D. K.; Kernie, S. G.; Parada, L. F. A Restricted Cell Population Propagates Glioblastoma Growth after Chemotherapy Nature 2012, 488, 522-526
24. Schepers, A. G.; Snippert, H. J.; Stange, D. E.; van den Born, M.; van Es, J. H.; van de Wetering, M.; Clevers, H. Lineage Tracing Reveals Lgr5+ Stem Cell Activity in Mouse Intestinal Adenomas Science 2012, 337, 730-735
25. Chaudhary, P. M.; Roninson, I. B. Expression and Activity of P-Glycoprotein, a Multidrug Efflux Pump, in Human Hematopoietic Stem Cells Cell 1991, 66, 85-94
26. Zinovyeva, M. V.; Zijlmans, J. M.; Fibbe, W. E.; Visser, J. W.; Belyavsky, A. V. Analysis of Gene Expression in Subpopulations of Murine Hematopoietic Stem and Progenitor Cells Exp. Hematol. 2000, 28, 318-334
27. Zhou, S.; Schuetz, J. D.; Bunting, K. D.; Colapietro, A. M.; Sampath, J.; Morris, J. J.; Lagutina, I.; Grosveld, G. C.; Osawa, M.; Nakauchi, H.; Sorrentino, B. P. The ABC Transporter Bcrp1/ABCG2 Is Expressed in a Wide Variety of Stem Cells and Is a Molecular Determinant of the Side-Population Phenotype Nat. Med. 2001, 7, 1028-1034
28. Marques, D. S.; Sandrini, J. Z.; Boyle, R. T.; Marins, L. F.; Trindade, G. S. Relationships between Multidrug Resistance (MDR) and Stem Cell Markers in Human Chronic Myeloid Leukemia Cell Lines Leuk. Res. 2010, 34, 757-762
29. Martins-Neves, S. R.; Lopes, á. O.; do Carmo, A.; Paiva, A. A.; Simões, P. C.; Abrunhosa, A. J.; Gomes, C. M. F. Therapeutic Implications of an Enriched Cancer Stem-like Cell Population in a Human Osteosarcoma Cell Line BMC Cancer 2012, 12, 139
30. Kingston, D. G. I.; Newman, D. J. Taxoids: Cancer-Fighting Compounds from Nature Curr. Opin. Drug Discovery Dev. 2007, 10, 130-144
31. Abidi, A. Cabazitaxel: A Novel Taxane for Metastatic Castration-Resistant Prostate Cancer-Current Implications and Future Prospects J. Pharmacol. Pharmacother. 2013, 4, 230-237
32. Bouchet, B. P.; Galmarini, C. M. Cabazitaxel, a New Taxane with Favorable Properties Drugs Today 2010, 46, 735-742
33. Pivot, X.; Koralewski, P.; Hidalgo, J. L.; Chan, A.; Gonçalves, A.; Schwartsmann, G.; Assadourian, S.; Lotz, J. P. A Multicenter Phase II Study of XRP6258 Administered as a 1-H I.V. Infusion Every 3 Weeks in Taxane-Resistant Metastatic Breast Cancer Patients Ann. Oncol. 2008, 19, 1547-1552
34. Liu, J.; Zhao, Y.; Guo, Q.; Wang, Z.; Wang, H.; Yang, Y.; Huang, Y. TAT-Modified Nanosilver for Combating Multidrug-Resistant Cancer Biomaterials 2012, 33, 6155-6161
35. Robert, J.; Jarry, C. Multidrug Resistance Reversal Agents J. Med. Chem. 2003, 46, 4805-4817
36. Nobili, S.; Landini, I.; Mazzei, T.; Mini, E. Overcoming Tumor Multidrug Resistance Using Drugs Able to Evade P-Glycoprotein or to Exploit Its Expression Med. Res. Rev. 2012, 32, 1220-1262
37. Shukla, S.; Wu, C.-P.; Ambudkar, S. V. Development of Inhibitors of ATP-Binding Cassette Drug Transporters: Present Status and Challenges Expert Opin. Drug Metab. Toxicol. 2008, 4, 205-223
38. Xia, C. Q.; Smith, P. G. Drug Efflux Transporters and Multidrug Resistance in Acute Leukemia: Therapeutic Impact and Novel Approaches to Mediation Mol. Pharmacol. 2012, 82, 1008-1021
39. Tsuruo, T.; Iida, H.; Tsukagoshi, S.; Sakurai, Y. Overcoming of Vincristine Resistance in P388 Leukemia in Vivo and in Vitro through Enhanced Cytotoxicity of Vincristine and Vinblastine by Verapamil Cancer Res. 1981, 41, 1967-1972
40. Cano-Gauci, D. F.; Riorda, J. R. Action of Calcium Antagonists on Multidrug Resistant Cells: Specific Cytotoxicity Independent of Increased Cancer Drug Accumulation Biochem. Pharmacol. 1987, 36, 2115-2123
41. Foxwell, B. M.; Mackie, A.; Ling, V.; Ryffel, B. Identification of the Multidrug Resistance-Related P-Glycoprotein as a Cyclosporine Binding Protein Mol. Pharmacol. 1989, 36, 543-546
42. Solary, E.; Velay, I.; Chauffert, B.; Caillot, D.; Bidan, J. M.; Dumas, M.; Casasnovas, O.; Guy, H. Quinine Circumvents the Doxorubicin Resistance of a Multidrug Resistant Human Leukemic Cell-Line, K562/DXR Nouv. Rev. Fr. Hématol. 1990, 32, 361-363
43. Stupp, R.; Bauer, J.; Pagani, O.; Gerard, B.; Cerny, T.; Sessa, C.; Bastian, G.; Sarkany, M.; Schläpfer, J.; Giroux, B.; Leyvraz, S. Ventricular Arrhythmia and Torsade de Pointe: Dose Limiting Toxicities of the MDR-Modulator S9788 in a Phase I Trial Ann. Oncol. 1998, 9, 1233-1242
44. Fonseca, S. B.; Kelley, S. O. Peptide-Chlorambucil Conjugates Combat Pgp-Dependent Drug Efflux ACS Med. Chem. Lett. 2011, 2, 419-423
45. Kaye, S. B. Reversal of Drug Resistance in Ovarian Cancer: Where Do We Go from Here? J. Clin. Oncol. 2008, 26, 2616-2618
46. Abbasi, M.; Lavasanifar, A.; Uluda, H. Recent Attempts at RNAi-Mediated P-Glycoprotein Downregulation for Reversal of Multidrug Resistance in Cancer Med. Res. Rev. 2013, 33, 33-53
47. Stege, A.; Krühn, A.; Lage, H. Overcoming Multidrug Resistance by RNA Interference. In Multi-Drug Resistance in Cancer; Zhou, J., Ed.; Methods in Molecular Biology; Humana Press: New York, 2010; Vol. 596, pp 447-465.
48. Elbashir, S. M.; Harborth, J.; Lendeckel, W.; Yalcin, A.; Weber, K.; Tuschl, T. Duplexes of 21-Nucleotide RNAs Mediate RNA Interference in Cultured Mammalian Cells Nature 2001, 411, 494-498
49. Nieth, C.; Priebsch, A.; Stege, A.; Lage, H. Modulation of the Classical Multidrug Resistance (MDR) Phenotype by RNA Interference (RNAi) FEBS Lett. 2003, 545, 144-150
50. Li, L.; Xu, J.; Min, T.; Huang, W. Reversal of MDR1 Gene-Dependent Multidrug Resistance Using Low Concentration of Endonuclease-Prepared Small Interference RNA Eur. J. Pharmacol. 2006, 536, 93-97
51. Stierlé, V.; Laigle, A.; Jollès, B. Modulation of the Efficiency of a siRNA Directed against MDR1 Expression in MCF7-R Cells When Combined with a Second siRNA Biochimie 2007, 89, 1033-1036
52. Xiao, H.; Wu, Z.; Shen, H.; Luo, A.-L.; Yang, Y.-F.; Li, X.-B.; Zhu, D.-Y. In Vivo Reversal of P-Glycoprotein-Mediated Multidrug Resistance by Efficient Delivery of Stealth RNAi Basic Clin. Pharmacol. Toxicol. 2008, 103, 342-348
53. Patil, Y. B.; Swaminathan, S. K.; Sadhukha, T.; Ma, L.; Panyam, J. The Use of Nanoparticle-Mediated Targeted Gene Silencing and Drug Delivery to Overcome Tumor Drug Resistance Biomaterials 2010, 31, 358-365
54. Mamot, C.; Drummond, D. C.; Hong, K.; Kirpotin, D. B.; Park, J. W. Liposome-Based Approaches to Overcome Anticancer Drug Resistance Drug Resist. Updates 2003, 6, 271-279
55. Štastný, M.; Strohalm, J.; Plocová, D.; Ulbrich, K.; Říhová, B. A Possibility to Overcome P-Glycoprotein (PGP)-Mediated Multidrug Resistance by Antibody-Targeted Drugs Conjugated to N -(2-Hydroxypropyl)methacrylamide (HPMA) Copolymer Carrier Eur. J. Cancer 1999, 35, 459-466
56. Fritzer, M.; Szekeres, T.; Szüts, V.; Jarayam, H. N.; Goldenberg, H. Cytotoxic Effects of a Doxorubicin-Transferrin Conjugate in Multidrug-Resistant KB Cells Biochem. Pharmacol. 1996, 51, 489-493
57. Hrkach, J.; Von Hoff, D.; Ali, M. M.; Andrianova, E.; Auer, J.; Campbell, T.; De Witt, D.; Figa, M.; Figueiredo, M.; Horhota, A.; Low, S.; McDonnell, K.; Peeke, E.; Retnarajan, B.; Sabnis, A.; Schnipper, E.; Song, J. J.; Song, Y. H.; Summa, J.; Tompsett, D.; Troiano, G.; Van Geen Hoven, T.; Wright, J.; LoRusso, P.; Kantoff, P. W.; Bander, N. H.; Sweeney, C.; Farokhzad, O. C.; Langer, R.; Zale, S. Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile Sci. Transl. Med. 2012, 4, 128ra39
58. Wu, J.; Lu, Y.; Lee, A.; Pan, X.; Yang, X.; Zhao, X.; Lee, R. J. Reversal of Multidrug Resistance by Transferrin-Conjugated Liposomes Co-Encapsulating Doxorubicin and Verapamil J. Pharm. Pharm. Sci. 2007, 10, 350-357
59. Wender, P. A.; Galliher, W. C.; Goun, E. A.; Jones, L. R.; Pillow, T. H. The Design of Guanidinium-Rich Transporters and Their Internalization Mechanisms Adv. Drug Delivery Rev. 2008, 60, 452-472
60. Rothbard, J. B.; Jessop, T. C.; Lewis, R. S.; Murray, B. A.; Wender, P. A. Role of Membrane Potential and Hydrogen Bonding in the Mechanism of Translocation of Guanidinium-Rich Peptides into Cells J. Am. Chem. Soc. 2004, 126, 9506-9507
61. Dubikovskaya, E. A.; Thorne, S. H.; Pillow, T. H.; Contag, C. H.; Wender, P. A. Overcoming Multidrug Resistance of Small-Molecule Therapeutics through Conjugation with Releasable Octaarginine Transporters Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 12128-12133
62. Wender, P. A.; Galliher, W. C.; Bhat, N. M.; Pillow, T. H.; Bieber, M. M.; Teng, N. N. H. Taxol-Oligoarginine Conjugates Overcome Drug Resistance in-Vitro in Human Ovarian Carcinoma Gynecol. Oncol. 2012, 126, 118-123
63. Meyer-Losic, F.; Quinonero, J.; Dubois, V.; Alluis, B.; Dechambre, M.; Michel, M.; Cailler, F.; Fernandez, A.-M.; Trouet, A.; Kearsey, J. Improved Therapeutic Efficacy of Doxorubicin through Conjugation with a Novel Peptide Drug Delivery Technology (Vectocell) J. Med. Chem. 2006, 49, 6908-6916
64. Aroui, S.; Brahim, S.; Waard, M. D.; Kenani, A. Cytotoxicity, Intracellular Distribution and Uptake of Doxorubicin and Doxorubicin Coupled to Cell-Penetrating Peptides in Different Cell Lines: A Comparative Study Biochem. Biophys. Res. Commun. 2010, 391, 419-425
65. Lindgren, M.; Rosenthal-Aizman, K.; Saar, K.; Eiríksdóttir, E.; Jiang, Y.; Sassian, M.; Östlund, P.; Hällbrink, M.; Langel, Ü. Overcoming Methotrexate Resistance in Breast Cancer Tumour Cells by the Use of a New Cell-Penetrating Peptide Biochem. Pharmacol. 2006, 71, 416-425
66. Stanzl, E. G.; Trantow, B. M.; Vargas, J. R.; Wender, P. A. Fifteen Years of Cell-Penetrating, Guanidinium-Rich Molecular Transporters: Basic Science, Research Tools, and Clinical Applications Acc. Chem. Res. 2013, 46, 2944-2954
67. Wender, P. A.; Cooley, C. B.; Geihe, E. I. Beyond Cell Penetrating Peptides: Designed Molecular Transporters Drug Discovery Today Technol. 2012, 9, e49-e55
68. Torchilin, V. P. Tat Peptide-Mediated Intracellular Delivery of Pharmaceutical Nanocarriers Adv. Drug Delivery Rev. 2008, 60, 548-558
69. Wender, P. A.; Mitchell, D. J.; Pattabiraman, K.; Pelkey, E. T.; Steinman, L.; Rothbard, J. B. The Design, Synthesis, and Evaluation of Molecules That Enable or Enhance Cellular Uptake: Peptoid Molecular Transporters Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 13003-13008
70. Lee, H.-L.; Dubikovskaya, E. A.; Hwang, H.; Semyonov, A. N.; Wang, H.; Jones, L. R.; Twieg, R. J.; Moerner, W. E.; Wender, P. A. Single-Molecule Motions of Oligoarginine Transporter Conjugates on the Plasma Membrane of Chinese Hamster Ovary Cells J. Am. Chem. Soc. 2008, 130, 9364-9370
71. Wender, P. A.; Rothbard, J. B.; Jessop, T. C.; Kreider, E. L.; Wylie, B. L. Oligocarbamate Molecular Transporters: Design, Synthesis, and Biological Evaluation of a New Class of Transporters for Drug Delivery J. Am. Chem. Soc. 2002, 124, 13382-13383
72. Wender, P. A.; Kreider, E.; Pelkey, E. T.; Rothbard, J.; VanDeusen, C. L. Dendrimeric Molecular Transporters: Synthesis and Evaluation of Tunable Polyguanidino Dendrimers That Facilitate Cellular Uptake Org. Lett. 2005, 7, 4815-4818
73. Chung, H.-H.; Harms, G.; Min Seong, C.; Choi, B. H.; Min, C.; Taulane, J. P.; Goodman, M. Dendritic Oligoguanidines as Intracellular Translocators Pept. Sci. 2004, 76, 83-96
74. Cooley, C. B.; Trantow, B. M.; Nederberg, F.; Kiesewetter, M. K.; Hedrick, J. L.; Waymouth, R. M.; Wender, P. A. Oligocarbonate Molecular Transporters: Oligomerization-Based Syntheses and Cell-Penetrating Studies J. Am. Chem. Soc. 2009, 131, 16401-16403
75. Maiti, K. K.; Jeon, O.-Y.; Lee, W. S.; Kim, D.-C.; Kim, K.-T.; Takeuchi, T.; Futaki, S.; Chung, S.-K. Design, Synthesis, and Membrane-Translocation Studies of Inositol-Based Transporters Angew. Chem., Int. Ed. 2006, 45, 2907-2912
76. Mazel, M.; Clair, P.; Rousselle, C.; Vidal, P.; Scherrmann, J. M.; Mathieu, D.; Temsamani, J. Doxorubicin-Peptide Conjugates Overcome Multidrug Resistance Anticancer Drugs 2001, 12, 107-116
77. Liang, J. F.; Yang, V. C. Synthesis of Doxorubicin-Peptide Conjugate with Multidrug Resistant Tumor Cell Killing Activity Bioorg. Med. Chem. Lett. 2005, 15, 5071-5075
78. Frankel, A. D.; Pabo, C. O. Cellular Uptake of the Tat Protein from Human Immunodeficiency Virus Cell 1988, 55, 1189-1193
79. Green, M.; Loewenstein, P. M. Autonomous Functional Domains of Chemically Synthesized Human Immunodeficiency Virus Tat Trans-Activator Protein Cell 1988, 55, 1179-1188
80. Vivès, E.; Brodin, P.; Lebleu, B. A Truncated HIV-1 Tat Protein Basic Domain Rapidly Translocates through the Plasma Membrane and Accumulates in the Cell Nucleus J. Biol. Chem. 1997, 272, 16010-16017
81. De Coupade, C.; Fittipaldi, A.; Chagnas, V.; Michel, M.; Carlier, S.; Tasciotti, E.; Darmon, A.; Ravel, D.; Kearsey, J.; Giacca, M.; Cailler, F. Novel Human-Derived Cell-Penetrating Peptides for Specific Subcellular Delivery of Therapeutic Biomolecules Biochem. J. 2005, 390, 407-418
82. Jones, L. R.; Goun, E. A.; Shinde, R.; Rothbard, J. B.; Contag, C. H.; Wender, P. A. Releasable Luciferin-Transporter Conjugates: Tools for the Real-Time Analysis of Cellular Uptake and Release J. Am. Chem. Soc. 2006, 128, 6526-6527
83. Saito, G.; Swanson, J. A.; Lee, K.-D. Drug Delivery Strategy Utilizing Conjugation via Reversible Disulfide Linkages: Role and Site of Cellular Reducing Activities Adv. Drug Delivery Rev. 2003, 55, 199-215
84. Mulders, T. M.; Keizer, J.; Breimer, D. D.; Mulder, G. J. In Vivo Characterization and Modulation of the Glutathione/glutathione S-Transferase System in Cancer Patients Drug Metab. Rev. 1995, 27, 191-229
85. Wender, P. A.; Goun, E. A.; Jones, L. R.; Pillow, T. H.; Rothbard, J. B.; Shinde, R.; Contag, C. H. Real-Time Analysis of Uptake and Bioactivatable Cleavage of Luciferin-Transporter Conjugates in Transgenic Reporter Mice Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 10340-10345
86. Pichler, A.; Prior, J. L.; Piwnica-Worms, D. Imaging Reversal of Multidrug Resistance in Living Mice with Bioluminescence: MDR1 P-Glycoprotein Transports Coelenterazine Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 1702-1707
87. Cragg, G. M.; Kingston, D. G. I.; Newman, D. J. Anticancer Agents from Natural Products, 2 nd ed.; CRC Press: Boca Raton, FL, 2011.
88. Elder, M. World Market for Cancer Therapeutics, 4 th ed.; Kalorama Information: Rockville, MD, 2012.
89. Krishna, R.; Mayer, L. D. Multidrug Resistance (MDR) in Cancer: Mechanisms, Reversal Using Modulators of MDR and the Role of MDR Modulators in Influencing the Pharmacokinetics of Anticancer Drugs Eur. J. Pharm. Sci. 2000, 11, 265-283
90. Kirschberg, T. A.; VanDeusen, C. L.; Rothbard, J. B.; Yang, M.; Wender, P. A. Arginine-Based Molecular Transporters: The Synthesis and Chemical Evaluation of Releasable Taxol-Transporter Conjugates Org. Lett. 2003, 5, 3459-3462
91. Gelderblom, H.; Verweij, J.; Nooter, K.; Sparreboom, A. Cremophor EL: The Drawbacks and Advantages of Vehicle Selection for Drug Formulation Eur. J. Cancer 2001, 37, 1590-1598
92. Lee, F. Y.; Vessey, A.; Rofstad, E.; Siemann, D. W.; Sutherland, R. M. Heterogeneity of Glutathione Content in Human Ovarian Cancer Cancer Res. 1989, 49, 5244-5248
93. Siegel, R.; Naishadham, D.; Jemal, A. Cancer Statistics, 2012 CA: Cancer J. Clin. 2012, 62, 10-29
94. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer, version 1, 2013.
95. Markman, M. Phase III Randomized Trial of 12 Versus 3 Months of Maintenance Paclitaxel in Patients With Advanced Ovarian Cancer After Complete Response to Platinum and Paclitaxel-Based Chemotherapy: A Southwest Oncology Group and Gynecologic Oncology Group Trial J. Clin. Oncol. 2003, 21, 2460-2465
96. Bookman, M. A.; Brady, M. F.; McGuire, W. P.; Harper, P. G.; Alberts, D. S.; Friedlander, M.; Colombo, N.; Fowler, J. M.; Argenta, P. A.; De Geest, K.; Mutch, D. G.; Burger, R. A.; Swart, A. M.; Trimble, E. L.; Accario-Winslow, C.; Roth, L. M. Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup J. Clin. Oncol. 2009, 27, 1419-1425
97. Armstrong, D. K.; Bundy, B.; Wenzel, L.; Huang, H. Q.; Baergen, R.; Lele, S.; Copeland, L. J.; Walker, J. L.; Burger, R. A. Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer N. Engl. J. Med. 2006, 354, 34-43
98. Nakase, I.; Konishi, Y.; Ueda, M.; Saji, H.; Futaki, S. Accumulation of Arginine-Rich Cell-Penetrating Peptides in Tumors and the Potential for Anticancer Drug Delivery in Vivo J. Controlled Release 2012, 159, 181-188
99. Kingston, D. G. Recent Advances in the Chemistry of Taxol J. Nat. Prod. 2000, 63, 726-734
100. Fonseca, S. B.; Pereira, M. P.; Kelley, S. O. Recent Advances in the Use of Cell-Penetrating Peptides for Medical and Biological Applications Adv. Drug Delivery Rev. 2009, 61, 953-964
101. Hampton, T. Researchers Devise Innovative Method to Overcome Cancer-Related Drug Resistance JAMA, J. Am. Med. Assoc. 2008, 300, 1507-1507
102. Said Hassane, F.; Saleh, A. F.; Abes, R.; Gait, M. J.; Lebleu, B. Cell Penetrating Peptides: Overview and Applications to the Delivery of Oligonucleotides Cell. Mol. Life Sci. 2010, 67, 715-726
103. Goun, E. A.; Shinde, R.; Dehnert, K. W.; Adams-Bond, A.; Wender, P. A.; Contag, C. H.; Franc, B. L. Intracellular Cargo Delivery by an Octaarginine Transporter Adapted to Target Prostate Cancer Cells through Cell Surface Protease Activation Bioconjugate Chem. 2006, 17, 787-796
104. Jiang, T.; Olson, E. S.; Nguyen, Q. T.; Roy, M.; Jennings, P. A.; Tsien, R. Y. Tumor Imaging by Means of Proteolytic Activation of Cell-Penetrating Peptides Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 17867-17872
105. Nguyen, Q. T.; Olson, E. S.; Aguilera, T. A.; Jiang, T.; Scadeng, M.; Ellies, L. G.; Tsien, R. Y. Surgery with Molecular Fluorescence Imaging Using Activatable Cell-Penetrating Peptides Decreases Residual Cancer and Improves Survival Proc. Natl. Acad. Sci. U.S.A. 2010, 107, 4317-4322
106. Miele, E.; Spinelli, G. P.; Miele, E.; Tomao, F.; Tomao, S. Albumin-Bound Formulation of Paclitaxel (Abraxane ABI-007) in the Treatment of Breast Cancer Int. J. Nanomed. 2009, 4, 99-105
107. Kukowska-Latallo, J. F.; Candido, K. A.; Cao, Z.; Nigavekar, S. S.; Majoros, I. J.; Thomas, T. P.; Balogh, L. P.; Khan, M. K.; Baker, J. R., Jr. Nanoparticle Targeting of Anticancer Drug Improves Therapeutic Response in Animal Model of Human Epithelial Cancer Cancer Res. 2005, 65, 5317-5324
108. Shi, N.-Q.; Gao, W.; Xiang, B.; Qi, X. R. Enhancing Cellular Uptake of Activable Cell-Penetrating Peptide-Doxorubicin Conjugate by Enzymatic Cleavage Int. J. Nanomed. 2012, 7, 1613-1621